Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
632.90
+12.76 (2.06%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
631.38
-1.52 (-0.24%)
Bozordan keyin: Jun 26, 2026, 7:38 PM EDT
Regeneron Pharmaceuticals, Inc. dunyo bo'ylab turli kasalliklarni davolash uchun dori-darmonlarni kashf qiladi, ixtiro qiladi, ishlab chiqadi, ishlab chiqaradi va tijoratlashtiradi. Kompaniya ko'z, allergik va yallig'lanish, yurak-qon tomir, metabolik, nevrologik, yuqumli va kam uchraydigan kasalliklarni; shuningdek, saraton, gematologik kasalliklarni davolash uchun mahsulot nomzodlarini ishlab chiqadi. Shuningdek, u nam yoshga bog'liq makula degeneratsiyasi va diabetik makula shishini davolash uchun EYLEA in'ektsiyalarini; miyopik xoriodeal neovaskulyarizatsiyani; diabetik retinopatiyani; neovaskulyar glaukomani; prematuralik retinopatiyasini; atopik dermatit va astmani davolash uchun Dupixent in'ektsiyasini; metastatik yoki mahalliy rivojlangan teri skuamoz hujayrali karsinomasi uchun Libtayo in'ektsiyasini; geterozigot oilaviy giperxolesterinemiya (HoFH)ni davolash uchun Praluent in'ektsiyasini; va revmatoid artrit uchun Kevzara eritmasini taklif etadi. U EYLEA 8 mg va EYLEAni ishlab chiqish va tijoratlashtirish bo'yicha Bayer bilan; ko'z va markaziy nerv sistemasida ifodalangan terapevtik kasallik maqsadlarini ko'rib chiqish orqali kasalliklar uchun RNAi terapevtik vositalarini kashf qilish, ishlab chiqish va tijoratlashtirish bo'yicha Alnylam Pharmaceuticals, Inc. bilan; nevrologik va mushak kasalliklariga qaratilgan terapiyalar uchun in vivo terapevtik rivojlanish uchun CRISPR/Cas9 gen tahrirlash texnologiyasini ilgari surish bo'yicha Intellia Therapeutics, Inc. bilan; HS-20094, er-xotin GLP-1/GIP retseptorining rivojlanish va tijoratlashtirish huquqlarini olish bo'yicha Hansoh Pharmaceuticals Group Company Limited bilan; va Alpha-1 antitrypsin etishmovchiligi uchun tadqiq qilinayotgan gen tahrirlash terapiyasi TSRA-196ni ishlab chiqish va tijoratlashtirish bo'yicha Tessera Therapeutics, Inc. bilan litsenziya va hamkorlik shartnomasiga ega. Qo'shimcha ravishda, kompaniya radiofarmatsvtika terapiyalarini ishlab chiqish va tijoratlashtirish bo'yicha Telix Pharmaceuticals Limited bilan strategik hamkorlikni amalga oshiradi. Shuningdek, u shartli ravishda faollashadigan bispesifik saraton terapiyalarini yaratish bo'yicha CytomX Therapeutics, Inc. bilan strategik hamkorlikni amalga oshiradi. Kompaniya 1988 yilda tashkil etilgan va Nyu-Yorkning Tarrytown shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrew J. Murphy Ph.D. | Executive VP of Research & Co-Chief Scientific Officer |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman |
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman |
| Mr. Christopher R. Fenimore CPA | Executive VP of Finance & CFO |
| Mr. Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply |
| Mr. Joseph J. LaRosa J.D. | Executive VP, General Counsel & Secretary |
| Mr. Rajesh Ahuja | Senior Vice President of Quality Assurance & Operations |
| Mr. Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis |
| Mr. Ryan Steinberger | Executive VP, Chief Digital & Technology Officer |
| Ms. Melissa Lozner | Senior VP & Chief Compliance Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-17 | 8-K | tm2618117d1_8k.htm |
| 2026-04-29 | 8-K | regn-20260429.htm |
| 2026-04-29 | 10-Q | regn-20260331.htm |
| 2026-04-24 | DEFA14A | a2026regeneronpharmaceutic.htm |
| 2026-04-24 | DEF 14A | regn-20260424.htm |
| 2026-04-24 | ARS | tm2611209d2_ars.pdf |
| 2026-04-08 | 8-K | tm2611354d1_8k.htm |
| 2026-02-04 | 10-K | regn-20251231.htm |
| 2026-01-30 | 8-K | regn-20260130.htm |
| 2026-01-12 | 8-K | tm262861d1_8k.htm |